-+ 0.00%
-+ 0.00%
-+ 0.00%
GSK wins FDA accelerated approval for Nelkarmi in previously treated ALK-positive lung cancer
Share
Listen to the news
GSK wins FDA accelerated approval for Nelkarmi in previously treated ALK-positive lung cancer
  • FDA grants accelerated approval to GSK’s Nelkarmi for adults with previously treated advanced ALK-positive non-small cell lung cancer.
  • The decision comes ahead of the agency’s original November 27, 2026, target action date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending